CEL-SCI Corporation news

   Watch this stock
Showing stories 11 - 20 of about 88   

Articles published

CVM 1.80 0.00 (0.00%)
price chart
CEL-SCI Announces Adjustment to Warrant Exercise Price
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 ...
CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical ...
On October 3, 2017, Lake Whillans Litigation Funding and CEL-SCI agreed to give an incentive to the law firm, Wilk Auslander, which is handling the case for CEL-SCI against the former CRO. Pursuant to this new arrangement, Lake Whillans has agreed to ...
Vienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial
Cel-Sci, led by CEO Geert Kersten, has said it spent more than a decade and $80 million in developing and validating the manufacturing process for Multikine.
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, “Method of Preparation and Composition of Peptide Constructs for Treatment of ...
CEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE: CVM) today announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with ...
CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial  Seeking Alpha
CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which ...
The Fundamental Case for and Against CEL-SCI Corporation (CVM)  StockNewsGazette
CEL-SCI Corporation (NYSEMKT:CVM) Is Finally Getting Some Reprieve
The latest announcement comes as a considerable relief for both CEL-SCI and its shareholders, given that the its only other development program is an early stage anal warts study, and should serve to bring about an inflection point in CEL-SCI's market ...
CEL-SCI Corporation (CVM) Stock: Gaining Big On FDA News  CNA Finance (press release)
CEL-SCI Corp (CVM) Says FDA Removes Clinical Hold on Phase 3 Head & Neck ...  StreetInsider.com
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine ...
CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head ...  Seeking Alpha
CEL-SCI Corporation (AMEX:CVM) Placed in the Hotbed: What Are The Numbers Saying?
Taking a look at some historical volatility numbers on shares of CEL-SCI Corporation (AMEX:CVM), we can see that the 12 month volatility is presently 94.402700.
CEL-SCI Co. (NYSEAMERICAN:CVM) Sees Significant Decrease in Short Interest  The Lincolnian Online